Abstract:Myocardial ischemia is a prevalent disorder causing heart failure. As cardiomyocyte death is the principal cause of cardiac functional deficits, a recognized treatment is to minimize cardiomyocyte death post myocardial ischemia. While extensive investigations have been conducted, few effective cardioprotective agents have been developed for clinical applications. The goal of this investigation is to test and establish a cardioprotective agent based on fibroblast growth factor 21 (FGF21), a secretory protein participating in innate cardioprotective responses. In myocardial ischemia induced by LAD coronary artery ligation in the mouse, hepatocytes upregulated FGF21 mRNA by 11 folds at 12 hrs, followed by an increase in the FGF21 protein level in hepatocytes and the serum. Administration of recombinant FGF21 to mice immediately post MI (50 ng/gm, IV, twice/day for 3 days) resulted in a significant reduction in the fraction of myocardial infarction (MI) with reference to the LV wall volume below the LAD ligation (38+/−5 and 21+/−4%, n=7, vs. albumin administration 51+/−8 and 31+/−5%, n=6, at day 1 and 10, respectively, p<0.05 for both times) in association with improved LV dp/dt. In FGF21 overexpressing mice, the volume fraction of MI (36+/−6%, n=6) was significantly lower than that in wildtype mice (48+/−6%, n=5, p<0.05) at day 1 post MI. Furthermore, FGF21 administration to normal mice induced phosphorylation of FGFR1, PI3K, Akt, and BAD in cardiomyocytes within 10 – 30 min. These molecules were also phosphorylated in cardiomyocytes within 1 day post MI. Injection of siRNA specific to FGFR1, PI3K, or Akt to the LV anterior wall at 6 locations about 2 mm apart (diffusion range of FITC-siRNA tested by fluorescence microscopy) 3 days prior to MI resulted in a reduction in the protein level of FGFR1, PI3K, or Akt by 65+/−9, 71+/−11, or 68+/−12%, respectively (n=3), within the region of siRNA injection at 1 day post MI in association with a reduction in BAD phosphorylation and an increase in the fraction of MI by 9+/−3, 8+/−2, or 11+/−3%, respectively (n=3). These observations suggested that FGF21 contributed to myocardial protection possibly via the FGFR1-PI3K-Akt-BAD signaling mechanisms and recombinant FGF21 may be potentially used as a cardioprotective agent.

Abstract 233: Engineering Growth Factors for Cardiomyocyte Survival and Regeneration Following Ischemic Injury

SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction.

Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor.

Limiting Cardiac Ischemic Injury by Pharmacological Augmentation of Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Signal Transduction

Abstract 723: Agonist of Growth Hormone Releasing Hormone Enhances Angiogenic Therapy by Mesenchymal Stem Cells

Human Growth Factor/Immunoglobulin Complexes for Treatment of Myocardial Ischemia-Reperfusion Injury

Requirements for Capsid-Binding and an Effector Function in Trimcyp-Mediated Restriction of Hiv-1

Regeneration of infarcted hearts by myocardial infarction-responsive injectable hydrogels with combined anti-apoptosis, anti-inflammatory and pro-angiogenesis properties

Abstract P278: Fibroblast Growth Factor 21 Mediated Protection of Ischemic Myocardium

Abstract P1103: A Combinatorial Stem Cell Therapy Using HiPSC-derived Cardiomyocytes And HiPSC-derived Mesenchymal Stem Cells For Cardiac Regeneration

Abstract P164: N-acetylglucosamine Conjugated to Nanoparticles Enhances Myocyte Uptake and Improves Delivery of a Small Molecule P38 Inhibitor for Postinfarct Healing

Abstract 11415: Enhancing Direct Cardiac Reprogramming Efficiency Using Small Molecules

Ischemic cardiac stromal fibroblast-derived protein mediators in the infarcted myocardium and transcriptomic profiling at single cell resolution

Injectable Citrate-Based Hydrogel As an Angiogenic Biomaterial Improves Cardiac Repair after Myocardial Infarction.

IGF-1C domain-modified hydrogel enhanced the efficacy of stem cells in the treatment of AMI

Artificial apoptotic cells/VEGF-loaded injectable hydrogel united with immunomodification and revascularization functions to reduce cardiac remodeling after myocardial infarction

Abstract 117: Stromal Cell-derived Factor-1 Gene Modified Endothelial Progenitor Cell Effectively Attenuated Ischemic Brain Injury in Mouse Model

Cardioprotection by GSK-3 inhibition: role of enhanced glycogen synthesis and attenuation of calcium overload

Isthmin-1 Alleviates Cardiac Ischaemia/reperfusion Injury Through Cgmp-Pkg Signalling Pathway

Treg-enhancing and Immunomodulating Microgel Scaffold Promotes Cell Ingrowth and Heart Function Recovery Post-Acute Myocardial Infarction in Vivo